Activity and safety of a vaccine in head and neck cancer

Phase 1

• Conditions: Head and neck cancer elective for surgery; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2020-000120-19-BE
• Lead Sponsor: Cliniques universitaires Saint-Luc

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-10
• Last Update Posted: 23 October 2023

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Age = 18
Squamous cell carcinome of hypopharynx, larynx, orolarynx, oral cavity
Elective for curative treatment
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

Distant metastases
Squamous cell carcinoma of nasal and sinusal cavities, nasopharynx and unknown primary

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified